Cell therapy

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

Don’t miss out: Last chance to register for the DDW CGT Showcase

Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and… Read More

#News

CAR-T therapy
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Characterise CAR-T cells: Address ‘on target, off tumour’ effects

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

#Cell therapy #Financing #Oncology #Phase I trial #Vittoria Biotherapeutics

Vittoria raises $25 million to accelerate T cell therapies

Immunotherapy company Vittoria Biotherapeutics has successfully completed a $25 million private financing round. This funding is a $10 million extension to its previous $15 million financing secured in November 2023. The latest round was led by Valley Forge Investment Corporation, with new investments from the Global BioAccess Fund and Hatch… Read More

#Business & Investment #News

Cell and gene therapy
#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

Webinar: Overcome the challenges of developing CGTs

Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and… Read More

#News

CAR-T therapy for leukaemia
#Autolus #CAR-T #Cell therapy #FDA #Immunotherapy #Leukaemia #Oncology

First FDA approval for new CAR-T therapy

The US Food and Drug Administration (FDA) has approved Autolus’ obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). The efficacy of obecabtagene autoleucel was evaluated in FELIX, an open-label, multicentre, single-arm trial that enrolled adults… Read More

#News #Regulatory #Trending News

Cytokines
#Cancer research #Cell therapy #Cytokines #Oncology

Harnessing nature’s ‘cues’ in the treatment of cancer

Megan Thomas spoke with Dan Passeri, CEO of Cue Biopharma, about why the company’s pipeline of cytokine-based drugs are so promising for cancer treatment. MT: Why is this a promising area of oncology research? DP: Cytokines, such as interleukin 2 (IL-2), are potent immunostimulant molecules and well-characterised activators of T… Read More

#Cancer Research #Exclusive Content

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Webinar: Enhance the characterisation of CAR-T cells

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

Register now: Discover areas of opportunity in CGT drug discovery

Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and… Read More

#News

CAR-T cell therapy
#CAR-T #Cell therapy #Financing #Fundraising #Haematology #March Biosciences #Oncology

March Bio raises $28.4m for autologous CAR-T therapy

Biotechnology company March Biosciences (March Bio) has announced the close of a $28.4 million oversubscribed Series A financing, having raised over $51 million to date. Mission BioCapital and 4BIO Capital led the financing, with participation from KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, and Mansueto Investments. Existing investors… Read More

#Business & Investment #News

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

What will the future bring in cell and gene therapies?

Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and… Read More

#News

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

Register now for DDW’s Cell & Gene Therapy Showcase

Join the DDW Cell & Gene Therapy Showcase, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery & development sector as well as highlighting challenges… Read More

#News

#Autoimmune disease #Cell therapy #Immuno-oncology #Kiji Therapeutics #Mergers and acquisitions #Monoclonal antibodies #REGiMMUNE #Stem cells

REGiMMUNE and Kiji Therapeutics announce intention to merge

Biopharmaceutical company REGiMMUNE and biotech Kiji Therapeutics have announced an intention to merge, creating a global Treg specialist that will target multiple indications. The new company, called REGiMMUNE/Kiji TX will combine the complimentary portfolio of platforms and therapies to create an international Treg biotech. Both companies have been focused on… Read More

#Business & Investment #News

Cell therapy
#Cell therapy #Immunotherapy #Oncology #Solid tumours #T cell activation #Turning Science into Business

Are TILs the next big thing in cancer treatment?

DDW’s Megan Thomas speaks with Dr Chantale Bernatchez, Director of Cell Therapy Process Development at CTMC, about tumour infiltrating lymphocyte (TIL) therapy and what's on the horizon for this new class of cell therapy. TIL therapy is a form of cancer immunotherapy. It's an autologous cell therapy, meaning cells are… Read More

#Cancer Research #Exclusive Content

#Business #Cell therapy #Oncology #Solid tumours #Turnstone Biologics

Turnstone Biologics reduces employee headcount by 60%

Turnstone Biologics has announced a “strategic prioritisation of its pipeline”, as well as a workforce reduction of approximately 60% and changes to its leadership team. The cuts are designed to allow the company to focus resources on the continued advancement of its Phase I programme, selected tumour-infiltrating lymphocyte (TIL) therapy… Read More

#Business & Investment #News #Trending News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene editing #Gene therapy

Cell & Gene Therapy Showcase

In this free online event leading industry figures outline areas of opportunity in CGT drug discovery and development sector as well as highlighting challenges facing the industry and how they can be overcome. It features presentations from experts in the field of cell and gene therapy drug development as well… Read More

Webinar date:
Co-sponsored by Benchling, Sartorius, Applied StemCell, and Elegen Bio
#Webinars

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology

Characterisation of CAR-T cells: Integrating live-cell analysis and high-throughput cytometry

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. This webinar, hosted by DDW and supported by Sartorius, explores the integration of live-cell analysis and high-throughput screening (HTS) by cytometry to enhance the characterisation of CAR-T cells. Key topics… Read More

Webinar date:
Supported by Sartorius
#Webinars